Dr. Matthew Macaluso
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- Rowan University School of Osteopathic Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 19
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Rowan University School of Osteopathic Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
AL license DO.2140
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 19
- Services billed
- 27
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 24 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 18 payments worth $9,166 in total to this clinician.
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $9,145 |
|---|---|
| Abbott Laboratories | $20.70 |
| Consulting Fee | $7,125 |
|---|---|
| Travel and Lodging | $1,469 |
| Food and Beverage | $572 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 14, 2025 | Consulting Fee CAPLYTA · PSYCHIATRY | $7,125 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 13, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to MIAMI, FL · in-kind | $641 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 13, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to MIAMI, FL · in-kind | $450 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 13, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CORAL GABLES, FL · in-kind | $360 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 13, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CORAL GABLES, FL | $10.00 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Mar 13, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CORAL GABLES, FL | $7.56 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $410,572 in research payments for these studies, mostly to the institutions running them.
- A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephri…
Janssen Research & Development, LLC - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - RECOVER
Livanova USA, Inc. - NCT06423430--Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Abbott Laboratories - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [D6-dm]/quinidine sulfate [q]) for the treatment…
Otsuka Pharmaceutical Development & Commercialization, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.